Opinion|Videos|July 1, 2024
Duration of Therapy and Dosing Strategies in RCC
Author(s)Martin H. Voss, MD
An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- In your experience, what is the optimal duration of treatment with lenvatinib in patients with advanced renal clear cell carcinoma?
- How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
- When do you consider switching therapies versus dose reductions to maintain treatment duration?
Advertisement
Related to this article
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5